6533b870fe1ef96bd12cf2aa
RESEARCH PRODUCT
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Cristina GuardiaAna RoviraBelen LloverasDavid CasadevallLuis Soria-jiménezJuan Carlos MonteroOriol Arpí-lluciàPilar ErolesFederico RojoBarbara GalbardiJoan AlbanellGiampaolo BianchiniJoaquín ArribasRaúl PeñaSonia ServitjaM. DugoLuca GianniAtanasio PandiellaSilvia MenendezAna LluchMohammada SabbaghiJuan Madoz-gúrpidesubject
Cancer ResearchStromal cellReceptor ErbB-2medicine.medical_treatmentNeuregulin-1Drug Evaluation PreclinicalBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabAntineoplastic Combined Chemotherapy Protocolsmental disordersmedicineTumor Cells CulturedHumansNeuregulin 1skin and connective tissue diseasesneoplasmsNeoadjuvant therapyRetrospective Studiesbiologybusiness.industryFibroblastsTrastuzumabmedicine.diseasebody regionsTreatment OutcomeOncologyCancer cellbiology.proteinCancer researchImmunohistochemistryFemalePertuzumabbusinessmedicine.drugdescription
[Purpose]: To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab.
year | journal | country | edition | language |
---|---|---|---|---|
2021-01-01 |